Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T18204
(Former ID: TTDI01734)
|
|||||
| Target Name |
Alpha-secretase (ASE)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Alzheimer disease [ICD-11: 8A20] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
| 1 | APH-1105 | Drug Info | Phase 2 | Alzheimer disease | [2] | |
| 2 | ID1201 | Drug Info | Phase 2 | Alzheimer disease | [3] | |
| 3 | APH-1104 | Drug Info | Phase 1 | Alzheimer disease | [4] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Modulator | [+] 2 Modulator drugs | + | ||||
| 1 | APH-1105 | Drug Info | [5] | |||
| 2 | APH-1104 | Drug Info | [4] | |||
| Enhancer | [+] 1 Enhancer drugs | + | ||||
| 1 | ID1201 | Drug Info | [6] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Alpha-secretase as a therapeutic target. Curr Alzheimer Res. 2007 Sep;4(4):412-7. | |||||
| REF 2 | ClinicalTrials.gov (NCT03806478) Safety, Tolerability and Efficacy Assessment of Intranasal Nanoparticles of APH-1105, A Novel Alpha Secretase Modulator For Mild to Moderate Cognitive Impairment Due to Alzheimer's Disease(AD). U.S.National Institutes of Health. | |||||
| REF 3 | ClinicalTrials.gov (NCT03363269) A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease. U.S.National Institutes of Health. | |||||
| REF 4 | Clinical pipeline report, company report or official report of Aphios | |||||
| REF 5 | Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021 May 25;7(1):e12179. | |||||
| REF 6 | Anti-amyloidogenic effects of ID1201, the ethanolic extract of the fruits of Melia toosendan, through activation of the phosphatidylinositol 3-kinase/Akt pathway. Environ Toxicol Pharmacol. 2014 Mar;37(2):513-20. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.